SLC22A1 Antibody

1. Two SNPs and two insertions/deletions were detected in exon 7 of SLC22A1. For exon 7, 1222AA carriers together with the presence of both the 8-bp insertion and 3-bp deletion, and M420del alleles showed higher possibility of developing resistance towards Imatinib mesylate (IM)treatment. Our results warrant the need of genotyping this SNP in terms of modulating IM treatment in chronic myeloid leukaemia patients. PMID: 30262695
2. data indicate that OCT1 may contribute to uptake metformin and regulate pancreatic stellate cells (PSCs) activity. OCT1 is a target of metformin in regulating PSCs activity. PMID: 29949790
3. inhibitory potency for morphine uptake was affected by the OCT1*2 allele. OCT2 showed only a limited uptake of ranitidine that was not significantly affected by the Ala270Ser polymorphism PMID: 29236753
4. Results indicated that OCT1 rs628031 and ABCG2 rs2231142 were associated with plasma lamotrigine concentrations in Han Chinese patients with epilepsy. PMID: 27610747
5. The additional role of SLC22A1/OCT1 genetics in M1 exposure in neonates. PMID: 27082504
6. The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. PMID: 26920453
7. Variants of SLC22A1 gene are associated with serum acylcarnitines and metabolic diseases. PMID: 28942964
8. summarize current understanding of human OCT1 transporter hepatic gene regulation and propose potential post-transcriptional regulation by predicted miRNAs. PMID: 27278216
9. The response to 6 months of metformin treatment (HbA1c , homeostasis model assessment for insulin resistance, fasting insulin, and glucose changes) did not differ between SLC22A1 wild-type subjects and carriers of presumably low-activity SLC22A1 alleles PMID: 27407018
10. we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression PMID: 28714373
11. This condensed chromatin structure is associated with binding of DNMT3B and decreased occupancy of OCT1 transcription factor at MAML2 enhancer, suggesting a role of DNMT3B in increasing methylation of MAML2 after stilbenoid treatment. PMID: 27207652
12. genetic association studies in population of patients newly diagnosed type 2 diabetes in Bosnia and Herzegovina: Data suggest that genetic variations in OCT1 [R61C (rs12208357); M420del (rs72552763)] are associated with severe intolerance/gastrointestinal side effects due to metformin use in patients with type 2 diabetes. PMID: 26605869
13. This study indicates a promising role for intratumoral OCT1 mRNA expression as a prognostic biomarker in therapeutic algorithms in HCC PMID: 26872727
14. Homozygous carriers of the polymorphic OCT1 C-allele had no metformin-related toxicity as compared with 41.9% for any metformin-related toxicity in carriers of at least one wild-type A-allele PMID: 25753371
15. hOCT1 is a suitable bendamustine transporter, thereby contributing to its cytotoxic effect depending upon the hOCT1 genetic variants expressed PMID: 25582574
16. A positive association was observed between the expression of the ABCB1 and ABCG2 transporter genes (r=0.407, P<0.05) while no association was observed between the expression of either of the ABC transporter genes with the OCT1 gene PMID: 26354214
17. Data indicate no association was found between genotypes of drug transporters ABCB1, ABCG2, OCT1 genetic polymorphisms and the occurrence of thrombocytopenia. PMID: 26546461
18. Findings suggest specific involvement of each organic cation transporters (OCT1-3) in drug transportation. PMID: 25883089
19. Data show that organic cation transporter (hOCT1) exon 2 GG homozygotes had higher imatinib (IM) levels than CG/CC genotypes, but the difference was not statistically significant. PMID: 24524306
20. Our data suggest that besides bodyweight, OCT1 and ABCC3 genotypes play a significant role in the pharmacokinetics of intravenous morphine and its metabolites in children PMID: 25155932
21. Nucleoside transporters and human OCT1 determine the cellular handling of DNA-methyltransferase inhibitors PMID: 24780098
22. The hOCT1 expression level can be an important predictor in CML patients treated with IM. PMID: 25358338
23. OCT1 plays a significant role in hepatic elimination of serotonin at the transporter level. PMID: 24688079
24. Clopidogrel/clopidogrel carboxylate are strong inhibitors and high affinity substrates of OCT1. PMID: 24530383
25. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. PMID: 24215657
26. The present study is the first report on the association of OCT-1 genetic polymorphisms with the overall development and jaundice-type progression of primary biliary cirrhosis. PMID: 23612856
27. Cellular uptake of imatinib is independent of OCT1, and therefore OCT1 is apparently not a valid biomarker for imatinib resistance. PMID: 24352644
28. OCT variants ( OCT1, OCT2 and ATM) were significantly associated with elevated baseline and glucose-induced C-peptide levels in polycystic ovary syndrome PMID: 24533710
29. Rhodamine 123 is a high-affinity substrate for both hOCT1 and hOCT2. PMID: 22913740
30. Decreased SLC22A1 mRNA expression is associated with low imatinib response in chronic myeloid leukemia. PMID: 24469953
31. Glucocorticoid receptor-induced expression of HNF4alpha may contribute to indirect OCT1 gene up-regulation by dexamethasone in primary human hepatocytes. PMID: 24399729
32. OCT1 genotypes play a significant role in intravenous morphine pharmacokinetics PMID: 23859569
33. Hepatocellular carcinoma and cholangiocarcinoma is accompanied by OCT1(SCC22A1) down-regulation together with the appearance of genetic variants that may affect the ability of these tumors to take up and respond to sorafenib (chemoresistance). PMID: 23532667
34. The SNP 408V>M (g.1222G>A) was present in 65% of CML patients & was associated in all cases with an 8-base-pair insertion (8(+) allele) at the 3' end of exon 7. Patients lacking 8(+) and 3(-) showed the best outcomes. PMID: 24117365
35. The expression of Oct1 mRNA is mediated by loss of T cells, but not B cells in immune-mediated liver disease. PMID: 23929842
36. The intron 1 evolutionary conserved region of OCT1 increases Oct1 promoter activity. PMID: 23922447
37. The accumulation of lamivudine in CD4 cells of HIV-infected patients is related to the expression of OCT1 and OCT2. PMID: 22875535
38. hOCT1 in the sinusoidal membrane of hepatocytes, and potentially the basolateral membrane of proximal tubule cells, is likely to play a role in the disposition of fluoroquinolone antimicrobial agents. PMID: 23545524
39. demonstrated that PER2 served as a transcriptional corepressor, which recruited polycomb proteins EZH2 and SUZ12 as well as HDAC2 to octamer transcription factor 1 (OCT1) (POU2F1) binding sites of the TWIST1 and SLUG promoters PMID: 23836662
40. The downregulation of OCT1 is associated with tumor progression and worse overall patient survival rates. PMID: 23440379
41. Expression levels of OCT1 were not changed in relation to the -1756 genotypes. PMID: 22498645
42. SLC22A1-ABCB1 haplotypes may influence IM pharmacokinetics in Asian CML patients. PMID: 23272163
43. This mini-review discusses structural requirements for both OCT1 and OCT2 versus the blood-brain barrier choline transporter (BBBCHT) are discussed and compared. PMID: 22483271
44. the data indicate that Oct1 regulates normal and cancer stem cell function PMID: 23144633
45. Seven polymorphisms in OCT1, OCT2, and MATE1 genes were compared between 53 type 2 diabetes patients with side effects of metformin and 193 metformin users without symptoms of metformin intolerance. PMID: 22735389
46. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. PMID: 23223357
47. High-dose imatinib leads to superior molecular responses in patients with low OCT-1 activity. PMID: 22207690
48. A substrate binding hinge domain is critical for transport-related structural changes of organic cation transporter 1. PMID: 22810231
49. data suggest a model for the sequence of binding events involved in synergistic gene regulation by Sox2 and Oct1 PMID: 22718759
50. evaluated the pretherapeutic mRNA expression of the hOCT1 (human organic cation transporter 1) gene in patients with chronic-phase (CP) chronic myeloid leukemia (CML) who varied in terms of their response to imatinib PMID: 22508387

显示更多

收起更多

HGNC: 10963

OMIM: 602607

KEGG: hsa:6580

STRING: 9606.ENSP00000355930

UniGene: Hs.117367